Scientists have redesigned a key piece of MRI hardware using metamaterials, allowing existing scanners to produce clearer ...

The Minimal Residual Disease pipeline presents key opportunities for drug development, highlighting promising therapies in various trial phases. Companies like AmMax Bio and Genentech leverage ...

Prime Medicine, Inc. wins arbitration vs. Beam Therapeutics Inc., advancing PM647 for AATD. Read more on PRME and BEAM stocks ...

Levacetylleucine (Aqneursa) improved neurologic symptoms and functioning in adults and children with ataxia-telangiectasia in ...

Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious underserved diseases, today announced ...

The "Diabetic Retinopathy - Pipeline Insight, 2026" report highlights growth opportunities with over 50 companies and 55 drugs in development across varied stages. Key prospects include advancing anti ...

In April 1965, three prominent Italian scientists called a press conference: Adriano Buzzati Traverso, geneticist and ...

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product ...

Warm compresses are frequently recommended indiscriminately, often without consideration of disease phenotype, inflammatory status or realistic thermal limitations. This article examines the ...

Systemic lupus erythematosus (SLE) is a chronic, complex autoimmune disease that can affect multiple organ systems, with ...

Results from the Phase 3 VELA clinical trials at Week 52 in adults with moderate-to-severe hidradenitis suppurativa (HS) demonstrate ...

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced, that ...